Cargando…

OA02-06 LB. Recombinant modified Vaccinia virus ankara expressing HIV-1 genes activates NK subset capable of controlling HIN infection in vitro

Detalles Bibliográficos
Autores principales:	Cummings, J, Arnold, V, Yarbrough, K, Didier, C, Levy, Y, Barré-Sinoussi, F, Scott-Algara, D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767538/ http://dx.doi.org/10.1186/1742-4690-6-S3-O18

Ejemplares similares

The CD85j(+) NK Cell Subset Potently Controls HIV-1 Replication in Autologous Dendritic Cells
por: Scott-Algara, Daniel, et al.
Publicado: (2008)

OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
por: Rolland, M, et al.
Publicado: (2009)

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission
por: Lingappa, JR, et al.
Publicado: (2009)

S100A9 protein is a novel ligand for the receptor CD85j and their interaction is implicated in the NK cell-mediated control of HIV-1 replication
por: Moreno Nieves, UY, et al.
Publicado: (2012)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

High Activation of γδ T Cells and the γδ2(pos) T-Cell Subset Is Associated With the Onset of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome, ANRS 12153 CAPRI NK
por: Pean, Polidy, et al.
Publicado: (2019)

S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells
por: Arnold, Vincent, et al.
Publicado: (2013)

OA02.06. Importance of drug authentication and standardization as per API with the example of Alpinia species
por: Nini, KG, et al.
Publicado: (2013)

S100A9 Tetramers, Which are Ligands of CD85j, Increase the Ability of MVA(HIV)-Primed NK Cells to Control HIV Infection
por: Moreno-Nieves, Uriel Y., et al.
Publicado: (2015)

OA03-06 LB. Unique stimulatory properties of myeloid dendritic cells in individuals with "elite" HIV-1 control
por: Huang, J, et al.
Publicado: (2009)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

P19-52 LB. Assessing and restructuring foreign gene insertion sites for enhanced stability of modified Vaccinia virus ankara recombinants expressing HIV genes
por: Wyatt, L, et al.
Publicado: (2009)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial
por: Currier, JR, et al.
Publicado: (2009)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice
por: Bohnen, C, et al.
Publicado: (2013)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

Tuberculosis but not Immune Reconstitution Inflammatory Syndrome (IRIS) prevents early and late NK cell degranulation reconstitution in HIV/TB co-infected patients
por: Pean, Polidy, et al.
Publicado: (2011)

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies
por: Garber, David A., et al.
Publicado: (2009)

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model
por: Nörder, Miriam, et al.
Publicado: (2010)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans
por: Capone, Stefania, et al.
Publicado: (2020)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
por: López-Camacho, César, et al.
Publicado: (2019)

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development
por: Volz, A., et al.
Publicado: (2017)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
por: Frey, Sharon E., et al.
Publicado: (2015)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
por: Jordan, Ingo, et al.
Publicado: (2013)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity
por: Alharbi, Naif Khalaf, et al.
Publicado: (2015)

Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
por: Zitzmann-Roth, Eva-Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v3sn99s4rod5fk57ue61pt6je9